A Global, Open-Label, Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Lay Description
Category
- Heart, Vascular and Blood
- Lungs, Breathing and Bronchial
- IRB Number
- 20190423HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Rodolfo Estrada Anzueto
(210) 617-5256
estradaanzue@uthscsa.edu
Regulatory Point of Contact
Fazal Hussain
(210) 567-3678
hussainf@uthscsa.edu
Regulatory Point of Contact
Shawn Lade
+1 (210) 450-8965
lade@uthscsa.edu
Regulatory Point of Contact
Deborah Levine
(210) 617-5256
levinedj@uthscsa.edu
Regulatory Point of Contact
Karl Mccloskey
mccloskeyk@uthscsa.edu
Local Recruitment Point of Contact
Karl Mccloskey
mccloskeyk@uthscsa.edu
Overall Recruitment Point of Contact
Rodolfo Estrada Anzueto
(210) 617-5256
estradaanzue@uthscsa.edu
Principal Investigator
Rodolfo Estrada Anzueto